Position in EXEL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$22,615,516
+$4,345,149 QoQ
Shares Held
415,650
-2.4% QoQ
Ownership
0.168%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#85
of 739 holders
Holding Since
Jun 2021
21 quarters on record
Voting authority
Sole 90%
Shared 0%
None 10%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026JACOBS LEVY EQUITY MANAGEMENT, INC holds $741,570,791 across 81 Biotechnology names. EXEL ranks #6 (3.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
256,503 | $159,939,880 | |
| 2 | RARE |
Ultragenyx Pharmaceutical Inc.
|
2,939,719 | $98,157,217 | |
| 3 | INCY |
Incyte Corp
|
731,774 | $82,953,900 | |
| 4 | CORT |
Corcept Therapeutics Inc
|
695,532 | $60,476,507 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
322,377 | $25,232,447 | |
| 6 | EXEL |
Exelixis, Inc.
This page
|
415,650 | $22,615,516 | |
| 7 | AUPH |
Aurinia Pharmaceuticals Inc.
|
1,231,516 | $20,898,826 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
60,986 | $18,358,615 |
All Filings in EXEL
Export CSV
21 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $22,615,516 | 415,650 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $18,270,367 | 425,982 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $20,781,249 | 474,133 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $19,527,466 | 472,820 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $44,431,449 | 1,007,973 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $52,266,056 | 1,415,657 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $50,152,597 | 1,506,084 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $54,035,243 | 2,082,283 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $56,650,982 | 2,521,183 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $57,093,169 | 2,405,949 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $56,734,262 | 2,364,913 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $72,109,238 | 3,300,194 | Shares | Sole | 2023-11-17 | |
| 2023-06-30 | $64,548,840 | 3,377,752 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $66,168,806 | 3,409,006 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $51,289,343 | 3,197,590 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $40,235,475 | 2,566,038 | Shares | Sole | 2022-11-15 | |
| 2022-06-30 | $48,293,218 | 2,319,559 | Shares | Sole | 2022-08-15 | |
| 2022-03-31 | $54,387,846 | 2,399,111 | Shares | Sole | 2022-05-16 | |
| 2021-12-31 | $41,011,618 | 2,243,524 | Shares | Sole | 2022-02-14 | |
| 2021-09-30 | $25,902,567 | 1,225,287 | Shares | Sole | 2021-11-15 | |
| 2021-06-30 | $1,986,799 | 109,045 | Shares | Sole | 2021-08-16 | |
| No filing history on record for this holder in this stock. | ||||||